神経障害性疼痛治療市場：疼痛タイプ、適応症、治療法、流通チャネル、エンドユーザー別-2025-2030年世界予測

神経障害性疼痛治療市場は、2023年に77億4,000万米ドルと評価され、2024年には85億9,000万米ドルに達すると予測され、CAGR 11.53％で成長し、2030年には166億1,000万米ドルに達すると予測されています。

神経障害性疼痛治療には、糖尿病、化学療法、身体的損傷など様々な原因による神経損傷に起因することが多い神経障害性疼痛に伴う不快感を緩和することを目的とした治療法や薬剤が含まれます。このような治療の必要性は、神経障害性疼痛の慢性的で衰弱しやすい性質によって強調され、QOLに大きな影響を与え、効果的な管理戦略が必要となります。神経障害性疼痛治療の適用範囲は、医薬品、医療機器、鍼治療や生活習慣の改善などの代替療法に及ぶ。最終用途としては、病院や外来診療所などのヘルスケア施設に加え、利便性を求める慢性疾患患者のための在宅ケア環境が主に含まれます。

市場の成長は、糖尿病やがんの有病率の増加、老人人口の増加、神経障害性疾患や利用可能な治療法に関する意識の高まりによって大きく後押しされています。ドラッグデリバリーシステムの技術的進歩や新規疼痛管理デバイスの開発は、市場拡大をさらに後押しします。さらに、個別化医療や、より良い診断と治療の個別化のための人工知能の統合には、患者の転帰を大幅に向上させるチャンスがあります。とはいえ、高い薬剤開発コスト、厳しい規制当局の承認、神経障害治療薬の長期使用に伴う副作用のリスクといった課題によって、市場開拓は難航しています。

この分野の技術革新は、非中毒性でより効果的な鎮痛薬の開発や、神経障害性障害の発症や進行を予防する神経保護剤の探索に重点を置くべきです。神経因性疼痛の遺伝的基盤の調査も、標的治療のブレークスルーにつながる可能性があります。市場競争は激しく、継続的な技術革新と研究開発投資がその原動力となっています。企業は、創薬を進めるために研究機関との提携や共同研究を優先し、進化する需要に効率的に対応するために患者中心の製品開発に取り組むことが推奨されます。

市場力学：急速に進化する神経障害性疼痛治療市場における主要市場インサイトの解明

神経障害性疼痛治療市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 神経障害性疼痛の人口増加
  • 世界のヘルスケア支出の増加
  • 神経障害性疼痛緩和剤と市販品の増加
• 市場抑制要因
  • 利用可能な治療オプションの認知度の低さ
• 市場機会
  • 新しい疼痛治療のイントロダクション
  • 緩和ケアに焦点を当てたプログラムや取り組み
• 市場の課題
  • 患者の神経障害性疼痛に適した治療を特定することの複雑さ

ポーターの5つの力：神経障害性疼痛治療市場をナビゲートする戦略ツール

ポーターの5つの力フレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：神経障害性疼痛治療市場における外部からの影響の把握

外部マクロ環境要因は、神経障害性疼痛治療市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析神経障害性疼痛治療市場における競合情勢の把握

神経障害性疼痛治療市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス神経障害性疼痛治療市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、神経障害性疼痛治療市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によりベンダーを明確かつ的確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨神経障害性疼痛治療市場における成功への道筋を描く

神経障害性疼痛治療市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を検討することで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 人口における神経障害性疼痛の増加
    • 世界のヘルスケア費の増加
    • 神経障害性疼痛緩和薬と市販薬の増加
  • 抑制要因
    • 利用可能な治療オプションに関する認識が限られている
  • 機会
    • 新しい痛み治療の代替法のイントロダクション
    • 緩和ケアに焦点を当てたプログラムと取り組み
  • 課題
    • 患者の神経障害性疼痛に適した治療を特定することの複雑さ
• 市場セグメンテーション分析
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 神経障害性疼痛治療市場痛みの種類別

• 尾骨痛
• 絞扼性神経障害
• 足の痛み
• 末梢神経障害
• 幻肢神経症
• 帯状疱疹後神経痛（PHN）
• 外傷後神経障害
• 三叉神経痛

第7章 神経障害性疼痛治療市場適応症別

• 化学療法誘発性末梢神経障害
• 糖尿病性神経障害
• 脊柱管狭窄症

第8章 神経障害性疼痛治療市場治療別

• 薬物
  • 抗うつ薬の種類
    • セロトニンノルアドレナリン
    • 三環系抗うつ薬
  • 薬の種類
  • マルチモーダルセラピー
  • NSAIDsタイプ
    • イブプロフェン
    • ナプロキセン
• 治療

第9章 神経障害性疼痛治療市場：流通チャネル別

• オンライン薬局
• 小売薬局・ドラッグストア

第10章 神経障害性疼痛治療市場：エンドユーザー別

• クリニック
• 病院

第11章 南北アメリカの神経障害性疼痛治療市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第12章 アジア太平洋地域の神経障害性疼痛治療市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第13章 欧州・中東・アフリカの神経障害性疼痛治療市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第14章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• Assertio Holdings, Inc.
• Astellas Pharma Inc.
• AstraZeneca PLC
• Aurobindo Pharma Limited
• Baxter International Inc.
• Biogen Inc.
• Bristol Myers Squibb Company
• Dr. Reddy's Laboratories Ltd.
• Eli Lilly and Company
• GlaxoSmithKline PLC
• Johnson and Johnson Services, Inc.
• Novartis AG
• Pfizer Inc.
• Sun Pharmaceutical Industries Limited

LIST OF FIGURES

• FIGURE 1. NEUROPATHY PAIN TREATMENT MARKET RESEARCH PROCESS
• FIGURE 2. NEUROPATHY PAIN TREATMENT MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 15. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 19. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 23. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 24. NEUROPATHY PAIN TREATMENT MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 25. NEUROPATHY PAIN TREATMENT MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. NEUROPATHY PAIN TREATMENT MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. NEUROPATHY PAIN TREATMENT MARKET DYNAMICS
• TABLE 7. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COCCYDYNIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ENTRAPMENT NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY FOOT PAIN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PERIPHERAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PHANTOM LIMB NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST HERPETIC NEURALGIA (PHN), BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY POST TRAUMATIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRIGEMINAL NEURALGIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CHEMOTHERAPY-INDUCED PERIPHERAL NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DIABETIC NEUROPATHY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SPINAL STENOSIS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY SEROTONIN NORADRENALINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TRICYCLIC ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MEDICATION TYPE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY MULTIMODAL THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY IBUPROFEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NAPROXEN, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY THERAPY, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY RETAIL PHARMACIES & DRUG STORES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 38. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY CLINICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 39. GLOBAL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 45. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 46. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 48. AMERICAS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 52. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 53. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 54. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 55. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 56. ARGENTINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 59. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 60. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 61. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 62. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 63. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. BRAZIL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 65. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 66. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 67. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 68. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 69. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 70. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 71. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 72. CANADA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 74. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 75. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 76. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 77. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 78. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 79. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 80. MEXICO NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 81. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 82. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 83. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 84. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 85. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 86. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 87. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 89. UNITED STATES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 90. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 91. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 92. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 93. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 94. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 95. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 96. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 97. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 98. ASIA-PACIFIC NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 99. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 100. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 101. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 102. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 103. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 104. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 105. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 106. AUSTRALIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 107. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 108. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 109. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 110. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 111. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 112. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 113. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 114. CHINA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 115. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 116. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 117. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 118. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 119. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 120. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 121. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. INDIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 123. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 124. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 125. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 126. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 127. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 128. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 129. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 130. INDONESIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 132. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 133. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 134. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 135. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 136. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 137. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 138. JAPAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 139. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 140. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 141. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 142. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 143. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 144. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 145. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. MALAYSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 147. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 148. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 149. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 150. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 151. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 152. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 153. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 154. PHILIPPINES NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 155. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 156. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 157. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 158. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 159. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 160. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 161. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 162. SINGAPORE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 163. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 164. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 165. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 166. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 167. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 168. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 169. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 170. SOUTH KOREA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 171. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 172. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 173. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 174. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 175. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 176. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 177. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 178. TAIWAN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 179. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 180. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 181. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 182. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 183. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 184. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 185. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 186. THAILAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 187. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 188. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 189. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 190. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 191. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 192. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 193. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 194. VIETNAM NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 196. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 197. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 198. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 199. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 200. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 201. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 202. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 203. EUROPE, MIDDLE EAST & AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 204. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 205. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 206. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 207. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 208. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 209. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 210. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 211. DENMARK NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 212. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 213. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 214. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 215. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 216. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 217. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 218. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 219. EGYPT NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 220. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 221. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 222. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 223. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 224. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 225. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 226. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 227. FINLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 228. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 229. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 230. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 231. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 232. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 233. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 234. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 235. FRANCE NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 236. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 237. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 238. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 239. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 240. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 241. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 242. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 243. GERMANY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 244. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 245. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 246. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 247. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 248. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 249. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 250. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 251. ISRAEL NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 252. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 253. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 254. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 255. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 256. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 257. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 258. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 259. ITALY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 260. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 261. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 262. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 263. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 264. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 265. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 266. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 267. NETHERLANDS NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 268. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 269. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 270. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 271. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 272. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 273. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 274. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 275. NIGERIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 276. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 277. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 278. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 279. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 280. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 281. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 282. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 283. NORWAY NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 284. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 285. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 286. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 287. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 288. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 289. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 290. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 291. POLAND NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 292. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 293. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 294. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 295. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 296. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 297. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 298. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 299. QATAR NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 300. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 301. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 302. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 303. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 304. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 305. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 306. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 307. RUSSIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 308. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 309. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 310. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 311. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 312. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 313. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 314. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 315. SAUDI ARABIA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 316. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 317. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 318. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
• TABLE 319. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DRUGS, 2018-2030 (USD MILLION)
• TABLE 320. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY ANTIDEPRESSANT DRUGS TYPE, 2018-2030 (USD MILLION)
• TABLE 321. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY NSAIDS TYPE, 2018-2030 (USD MILLION)
• TABLE 322. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 323. SOUTH AFRICA NEUROPATHY PAIN TREATMENT MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 324. SPAIN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY PAIN TYPE, 2018-2030 (USD MILLION)
• TABLE 325. SPAIN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
• TABLE 326. SPAIN NEUROPATHY PAIN TREATMENT MARKET SIZE, BY TREATMENT, 20

The Neuropathy Pain Treatment Market was valued at USD 7.74 billion in 2023, expected to reach USD 8.59 billion in 2024, and is projected to grow at a CAGR of 11.53%, to USD 16.61 billion by 2030.

Neuropathy pain treatment encompasses therapies and medications aimed at alleviating the discomfort associated with neuropathic pain, a condition often resulting from nerve damage due to various causes like diabetes, chemotherapy, or physical injury. The necessity of such treatments is underscored by the chronic and debilitating nature of neuropathic pain, which can significantly impact quality of life and necessitates effective management strategies. The application scope of neuropathy pain treatment spans across pharmaceuticals, medical devices, and alternative therapies such as acupuncture and lifestyle modifications. End-use predominantly involves healthcare facilities like hospitals and outpatient clinics, alongside home care settings for chronic sufferers seeking convenience.

The market's growth is largely propelled by the increasing prevalence of diabetes and cancer, rising geriatric population, and the escalating awareness about neuropathic conditions and available treatments. Technological advancements in drug delivery systems and the development of novel pain management devices further fuel market expansion. Moreover, there are opportunities in personalized medicine and the integration of artificial intelligence for better diagnosis and treatment personalization, which can significantly elevate patient outcomes. Nonetheless, market growth is challenged by factors like high drug development costs, stringent regulatory approvals, and the risk of side effects associated with long-term usage of neuropathic medications.

Innovation in this sector should focus on developing non-addictive and more effective analgesics, as well as exploring neuroprotective agents that can prevent the onset or progression of neuropathic damage. Researching the genetic basis of neuropathic pain could also lead to breakthroughs in targeted therapy. The nature of the neuropathy pain treatment market is highly competitive, driven by continuous innovation and R&D investments. Companies are recommended to prioritize partnerships and collaborations with research institutions to advance drug discovery and to engage in patient-centric product development to meet evolving demands efficiently.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Neuropathy Pain Treatment Market

The Neuropathy Pain Treatment Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Rise in neuropathic pain among population
  • Increasing global healthcare expenditure
  • Growing number of neuropathic pain relievers and over-the-counter products
• Market Restraints
  • Limited awareness of available treatment options
• Market Opportunities
  • Introduction of novel pain treatment alternatives
  • Programs and initiatives focusing on palliative care
• Market Challenges
  • Complexity in identifying the treatment suitable for neuropathic pains in a patient

Porter's Five Forces: A Strategic Tool for Navigating the Neuropathy Pain Treatment Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Neuropathy Pain Treatment Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Neuropathy Pain Treatment Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Neuropathy Pain Treatment Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Neuropathy Pain Treatment Market

A detailed market share analysis in the Neuropathy Pain Treatment Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Neuropathy Pain Treatment Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Neuropathy Pain Treatment Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Neuropathy Pain Treatment Market

A strategic analysis of the Neuropathy Pain Treatment Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Neuropathy Pain Treatment Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Assertio Holdings, Inc., Astellas Pharma Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biogen Inc., Bristol Myers Squibb Company, Dr. Reddy's Laboratories Ltd., Eli Lilly and Company, GlaxoSmithKline PLC, Johnson and Johnson Services, Inc., Novartis AG, Pfizer Inc., and Sun Pharmaceutical Industries Limited.

Market Segmentation & Coverage

This research report categorizes the Neuropathy Pain Treatment Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Pain Type, market is studied across Coccydynia, Entrapment Neuropathy, Foot Pain, Peripheral Neuropathy, Phantom Limb Neuropathy, Post Herpetic Neuralgia (PHN), Post Traumatic Neuropathy, and Trigeminal Neuralgia.
• Based on Indication, market is studied across Chemotherapy-Induced Peripheral Neuropathy, Diabetic Neuropathy, and Spinal Stenosis.
• Based on Treatment, market is studied across Drugs and Therapy. The Drugs is further studied across Antidepressant Drugs Type, Medication Type, Multimodal Therapy, and NSAIDs Type. The Antidepressant Drugs Type is further studied across Serotonin Noradrenaline and Tricyclic Antidepressants. The NSAIDs Type is further studied across Ibuprofen and Naproxen.
• Based on Distribution Channel, market is studied across Online Pharmacies and Retail Pharmacies & Drug Stores.
• Based on End-User, market is studied across Clinics and Hospitals.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Rise in neuropathic pain among population
    • 5.1.1.2. Increasing global healthcare expenditure
    • 5.1.1.3. Growing number of neuropathic pain relievers and over-the-counter products
  • 5.1.2. Restraints
    • 5.1.2.1. Limited awareness of available treatment options
  • 5.1.3. Opportunities
    • 5.1.3.1. Introduction of novel pain treatment alternatives
    • 5.1.3.2. Programs and initiatives focusing on palliative care
  • 5.1.4. Challenges
    • 5.1.4.1. Complexity in identifying the treatment suitable for neuropathic pains in a patient
• 5.2. Market Segmentation Analysis
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Neuropathy Pain Treatment Market, by Pain Type

• 6.1. Introduction
• 6.2. Coccydynia
• 6.3. Entrapment Neuropathy
• 6.4. Foot Pain
• 6.5. Peripheral Neuropathy
• 6.6. Phantom Limb Neuropathy
• 6.7. Post Herpetic Neuralgia (PHN)
• 6.8. Post Traumatic Neuropathy
• 6.9. Trigeminal Neuralgia

7. Neuropathy Pain Treatment Market, by Indication

• 7.1. Introduction
• 7.2. Chemotherapy-Induced Peripheral Neuropathy
• 7.3. Diabetic Neuropathy
• 7.4. Spinal Stenosis

8. Neuropathy Pain Treatment Market, by Treatment

• 8.1. Introduction
• 8.2. Drugs
  • 8.2.1. Antidepressant Drugs Type
    • 8.2.1.1. Serotonin Noradrenaline
    • 8.2.1.2. Tricyclic Antidepressants
  • 8.2.2. Medication Type
  • 8.2.3. Multimodal Therapy
  • 8.2.4. NSAIDs Type
    • 8.2.4.1. Ibuprofen
    • 8.2.4.2. Naproxen
• 8.3. Therapy

9. Neuropathy Pain Treatment Market, by Distribution Channel

• 9.1. Introduction
• 9.2. Online Pharmacies
• 9.3. Retail Pharmacies & Drug Stores

10. Neuropathy Pain Treatment Market, by End-User

• 10.1. Introduction
• 10.2. Clinics
• 10.3. Hospitals

11. Americas Neuropathy Pain Treatment Market

• 11.1. Introduction
• 11.2. Argentina
• 11.3. Brazil
• 11.4. Canada
• 11.5. Mexico
• 11.6. United States

12. Asia-Pacific Neuropathy Pain Treatment Market

• 12.1. Introduction
• 12.2. Australia
• 12.3. China
• 12.4. India
• 12.5. Indonesia
• 12.6. Japan
• 12.7. Malaysia
• 12.8. Philippines
• 12.9. Singapore
• 12.10. South Korea
• 12.11. Taiwan
• 12.12. Thailand
• 12.13. Vietnam

13. Europe, Middle East & Africa Neuropathy Pain Treatment Market

• 13.1. Introduction
• 13.2. Denmark
• 13.3. Egypt
• 13.4. Finland
• 13.5. France
• 13.6. Germany
• 13.7. Israel
• 13.8. Italy
• 13.9. Netherlands
• 13.10. Nigeria
• 13.11. Norway
• 13.12. Poland
• 13.13. Qatar
• 13.14. Russia
• 13.15. Saudi Arabia
• 13.16. South Africa
• 13.17. Spain
• 13.18. Sweden
• 13.19. Switzerland
• 13.20. Turkey
• 13.21. United Arab Emirates
• 13.22. United Kingdom

14. Competitive Landscape

• 14.1. Market Share Analysis, 2023
• 14.2. FPNV Positioning Matrix, 2023
• 14.3. Competitive Scenario Analysis
• 14.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. Assertio Holdings, Inc.
• 3. Astellas Pharma Inc.
• 4. AstraZeneca PLC
• 5. Aurobindo Pharma Limited
• 6. Baxter International Inc.
• 7. Biogen Inc.
• 8. Bristol Myers Squibb Company
• 9. Dr. Reddy's Laboratories Ltd.
• 10. Eli Lilly and Company
• 11. GlaxoSmithKline PLC
• 12. Johnson and Johnson Services, Inc.
• 13. Novartis AG
• 14. Pfizer Inc.
• 15. Sun Pharmaceutical Industries Limited